# Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

> **NCT03213041** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 100 (estimated)

## Conditions studied

- Estrogen Receptor Negative
- Estrogen Receptor Positive
- HER2/Neu Negative
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03213041
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-09-14
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213041, "Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03213041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*